Chiba University Hospital Researcher Furthers Understanding of Pancreatic Cancer (Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer).

A recent study conducted at Chiba University Hospital in Japan investigated the effectiveness of gemcitabine (GEM) + nab-paclitaxel (nab-PTX) combination therapy in elderly patients with pancreatic cancer. The study included 160 patients and compared the treatment efficacy and prognostic factors between non-elderly and elderly patients. The results showed that the GEM + nab-PTX regimen had a similar antitumor effect in both age groups. However, the prognostic factors were reduced in the elderly, suggesting the need to identify specific factors to determine the appropriate treatment for elderly patients. [Extracted from the article]

Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)